Mizuho Securities analyst Vamil Divan maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $27.00. The company's shares closed last Wednesday at $18.58. According to TipRanks.com, Divan is a 1-star analyst with an average return of -2.5% and a 45.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and Xeris Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $28.64 average price target, representing a 64.7% upside.
https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-hold-rating-for-acadia-pharmaceuticals-acad?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.